Invivyd reports preliminary Q4 revenue of $13.8M; positive Phase 1/2 data for VYD2311

Invivyd, Inc.

Preliminary Q4 PEMGARDA net revenue $13.8M, 48% growth over Q3; total operating costs $32M, 55% reduction.
Cash and equivalents $69.3M; accounts receivable $10.9M; targets near-term profitability by end of 1H 2025.
Positive Phase 1/2 data for VYD2311: safety mild/moderate, serum concentrations high at Day 65, half-life not reached.
VYD2311 shows average 17-fold greater in vitro neutralization potency vs pemivibart across contemporary SARS-CoV-2 variants.
Potential clinical profile: 70-90% protection from symptomatic COVID-19 with once- or twice-annual dosing, also as treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.